Page last updated: 2024-11-05

carnosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

polaprezinc: stimulates bone growth [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID439224
CHEMBL ID242948
CHEBI ID15727
SCHEMBL ID33769
MeSH IDM0003535

Synonyms (102)

Synonym
AC-17084
n(alpha)-(beta-alanyl)-l-histidine
CHEBI:15727 ,
SPECTRUM5_000605
DIVK1C_006470
KBIO1_001414
SDCCGMLS-0066726.P001
z-103
polaprezinc
SPECTRUM4_001673
SPECTRUM_001178
beta-alanyl-l-histidine
n-2-m
nsc 524045
brn 0087671
l-histidine, beta-alanyl-
karnozzn
einecs 206-169-9
NCGC00017390-01
tnp00340
BSPBIO_002624
karnozin
l-histidine, n-.beta.-alanyl-
ignotine
.beta.-alanyl-l-histidine
l-carnosine
nsc-524045
C00386 ,
nalpha-(beta-alanyl)-l-histidine
305-84-0
carnosine ,
l-carnosine, ~99%, crystalline
NCGC00142487-01
z 103
KBIO3_002124
KBIO2_001658
KBIOSS_001658
KBIO2_006794
KBIO2_004226
KBIOGR_002225
SPECTRUM3_001212
SPECTRUM2_000454
SPECPLUS_000374
SPBIO_000528
SPECTRUM1500944
beta-alanylhistidine
l-ignotine
A0222
CHEMBL242948
BMSE000246
(2s)-2-(3-aminopropanoylamino)-3-(1h-imidazol-5-yl)propanoic acid
NCGC00017390-02
(2s)-2-(3-aminopropanoylamino)-3-imidazol-4-ylpropanoic acid
8ho6pvn24w ,
unii-8ho6pvn24w
4-25-00-04381 (beilstein handbook reference)
BMSE001002
AKOS010421481
AKOS015963345
CCG-38696
carnosine [vandf]
carnosine [mi]
carnosine [inci]
carnosine [who-dd]
(2s)-2-(3-aminopropanamido)-3-(1h-imidazol-4-yl)propanoic acid
gtpl4559
STL466172
SCHEMBL33769
betaala-his
3-aminopropionyl-histidine
beta-alanyl-l-histidin
AC-19690
.beta.-alanylhistidine
AC-31940
b-alanyl-l-histidine
mfcd00005207
(2s)-2-(3-aminopropanamido)-3-(1h-imidazol-5-yl)propanoic acid
sr-05000002473
SR-05000002473-1
bdbm50485554
H11980
l-carnosine, vetec(tm) reagent grade, 98%
n-(3-aminopropanoyl)histidine
sevitin
b-alanylhistidine
n-b-alanyl-l-histidine
n-(b-alanyl)-l-histidine
1370422-07-3
HY-W013494
CS-W014210
DB11695
Q413822
(s)-2-(3-aminopropanamido)-3-(1h-imidazol-4-yl)propanoic acid
(s)-2-(3-aminopropanamido)-3-(1h-imidazol-5-yl)propanoic acid
AS-12570
8v0 ,
(2~{s})-2-(3-azanylpropanoylamino)-3-(1~{h}-imidazol-4-yl)propanoic acid
DTXSID80879594
S5226
(3-aminopropanoyl)-l-histidine
EN300-302338
b-ala-his-oh

Research Excerpts

Toxicity

Carnosine is an endogenous di-peptide (β-alanine-L-histidine) which promotes physiological homeostasis in part by conjugating to and neutralising toxic aldehydes. In safety and tolerability assessments, carnosine did not exhibit any evidence of adverse effects or toxicity.

ExcerptReferenceRelevance
" LD50 values in mice were 1269 mg/kg for males and 1331 mg/kg for females by the oral route, 220 mg/kg for males and 165 mg/kg for females by the intraperitoneal route, and 758 mg/kg for males and 874 mg/kg for females by the subcutaneous route."( Single dose toxicity study on catena-(S)-[mu-[N alpha-(3-aminopropionyl) histidinato(2-)-N1,N2,O:N tau]-zinc] in mice and rats.
Aruga, F; Kato, T; Matsuda, K; Morikami, H; Shibata, K, 1991
)
0.28
" Furthermore, in the 600 mg/kg group changes in urine volume, blood urea nitrogen and weight of kidneys were observed, suggesting that Z-103 may have had adverse effects on the kidney."( Repeated dose toxicity studies on catena-(S)-[mu-[N alpha-(3-aminopropionyl) histidinato(2-)-N1,N2,O:N tau]-zinc] in rats.
Aruga, H; Matsuda, K; Mera, Y; Saik, Y; Taniguchi, Y; Wada, H, 1991
)
0.28
"The preventive effect of beta-alanyl-L-histidinato zinc (AHZ) on the toxic action of aluminium on bone metabolism was investigated in the femoral diaphysis of weanling rats."( Beta-alanyl-L-histidinato zinc prevents the toxic effect of aluminium on bone metabolism in weanling rats.
Ozaki, K; Yamaguchi, M, 1990
)
0.28
" Toxic effects of the peptide were seen at 200 microg/ml A beta using a mitochondrial dehydrogenase activity (MTT) reduction assay, lactate dehydrogenase release and glucose consumption."( Toxic effects of beta-amyloid(25-35) on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and beta-alanine.
Abbott, JN; Himsworth, DT; Hipkiss, AR; Preston, JE; Romero, IA, 1998
)
0.3
"Radiation-induced stomatitis is one of the adverse effects of total body irradiation(TBI)."( [Efficacy and safety of polaprezinc as a preventive drug for radiation-induced stomatitis].
Chikaaki, M; Hiromi, F; Keita, T; Masayuki, F; Masayuki, I; Miwa, I; Norihiko, K; Norio, N; Toshihiko, I, 2002
)
0.31
" No adverse reaction owing to the ingestion of P-CMC was observed."( [Efficacy and safety of polaprezinc as a preventive drug for radiation-induced stomatitis].
Chikaaki, M; Hiromi, F; Keita, T; Masayuki, F; Masayuki, I; Miwa, I; Norihiko, K; Norio, N; Toshihiko, I, 2002
)
0.31
" Patients and the public expect that safe and cost-effective cataract medical care with N-acetylcarnosine therapeutic platform should be commissioned for them."( State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatm
Babizhayev, MA; Kasus-Jacobi, A, 2009
)
0.35
" Toxic effects of homocysteine and the product of its spontaneous oxidation, homocysteic acid, are based on their ability to activate NMDA receptors, increasing intracellular levels of ionized calcium and reactive oxygen species."( Molecular mechanisms of homocysteine toxicity.
Boldyrev, AA, 2009
)
0.35
"3%) free of adverse events (AE)."( Zinc-carnosine and vitamin E supplementation does not ameliorate gastrointestinal side effects associated with ciclosporin therapy of canine atopic dermatitis.
Rosenkrantz, WS; Roycroft, LM; Wilson, LS, 2011
)
0.37
" SDM's toxic effects were tested on neuronal-like SH-SY5Y cells, causing an exponential decrease in viability, while human dermal fibroblasts were completely resistant to the toxic effects."( Carnosine protects against the neurotoxic effects of a serotonin-derived melanoid.
Brownrigg, TD; Fibuch, EE; Seidler, NW; Theisen, CS, 2011
)
0.37
" In safety and tolerability assessments, carnosine did not exhibit any evidence of adverse effects or toxicity."( Safety and efficacy evaluation of carnosine, an endogenous neuroprotective agent for ischemic stroke.
Bae, ON; Baek, SH; Bhatt, A; Dorrance, A; Farooq, MU; Fitzgerald, SD; Lee, KY; Majid, A; Naravelta, B; Rumbeiha, W; Serfozo, K, 2013
)
0.39
"Lead (Pb)-induced reproductive toxicity is a well-characterized adverse effect associated with this heavy metal."( Carnosine and Histidine Supplementation Blunt Lead-Induced Reproductive Toxicity through Antioxidative and Mitochondria-Dependent Mechanisms.
Ahmadi, F; Heidari, R; Jamshidzadeh, A; Javanmard, N; Khodaei, F; Mousapour, S; Ommati, MM; Shirazi Yeganeh, B; Sun, Z; Zamiri, MJ, 2019
)
0.51
" All doses of polaprezinc were tolerable, but a dose-response relationship with adverse events (AEs) was observed in gastrointestinal disorders."( Efficacy and Safety of Polaprezinc (Zinc Compound) on Zinc Deficiency: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials Using Individual Patient Data.
Furihata, K; Miwa, T; Naito, Y; Oba, K; Sakagami, M; Tsuchikawa, M, 2020
)
0.56
" According to the amyloid cascade hypothesis, increases in extracellular amyloid-β (Aβ) levels give rise to different aggregated species, such as protofibrils, fibrils and oligomers, with oligomers being the more toxic species for cells."( Hyaluronan-carnosine conjugates inhibit Aβ aggregation and toxicity.
Ahmed, IMM; Bellia, F; Greco, V; La Mendola, D; Messina, L; Naletova, I; Rizzarelli, E; Satriano, C; Sciuto, S; Vaccaro, S, 2020
)
0.56
" The purpose of this review is to examine the existing literature regarding the benefits of histidine intake, the adverse effects of excess histidine, and the upper tolerance level for histidine."( Benefits and Adverse Effects of Histidine Supplementation.
Gheller, ME; Thalacker-Mercer, AE, 2020
)
0.56
" Patient background, oral adverse events, the incidence and severity of systemic adverse events (sepsis/septic shock, acute graft-versus-host disease (GVHD) after transplantation), and outcomes (survival/death) were compared between groups treated with and without PPAA."( Oral management with polaprezinc solution reduces adverse events in haematopoietic stem cell transplantation patients.
Arai, H; Haruyama, Y; Ishihama, H; Kamimura, R; Kawamata, H; Kobashi, G; Komiyama, Y; Mitani, K; Sawatani, Y; Tsubura-Okubo, M; Uchida, D, 2021
)
0.62
" Carnosine is an endogenous di-peptide (β-alanine-L-histidine) which promotes physiological homeostasis in part by conjugating to and neutralising toxic aldehydes."( Protocol to assess the efficacy of carnosine supplementation in mitigating the adverse cardiovascular responses to particulate matter (PM) exposure: the Nucleophilic Defense Against PM Toxicity (NEAT) trial.
Amraotkar, AA; Baba, SP; Bhatnagar, A; Crandell, CE; DeFilippis, AP; Keith, RJ; Lorkiewicz, P; O'Toole, TE; Pariser, GL; Pope Iii, CA; Rai, SN; Wingard, CJ, 2020
)
0.56
" This trial will enroll 240 participants over 2 years and determine if carnosine supplementation mitigates the adverse effects of PM inhalation."( Protocol to assess the efficacy of carnosine supplementation in mitigating the adverse cardiovascular responses to particulate matter (PM) exposure: the Nucleophilic Defense Against PM Toxicity (NEAT) trial.
Amraotkar, AA; Baba, SP; Bhatnagar, A; Crandell, CE; DeFilippis, AP; Keith, RJ; Lorkiewicz, P; O'Toole, TE; Pariser, GL; Pope Iii, CA; Rai, SN; Wingard, CJ, 2020
)
0.56
" Any post-treatment adverse events were recorded."( Clinical Efficacy and Safety of Non-Cross-Linked Hyaluronic Acid Combined with L-carnosine for Horizontal Neck Wrinkles Treatment.
Gao, H; Liu, Y; Niu, H; Ren, S; Tan, Y; Wang, L; Wang, S, 2021
)
0.62
" The Nrf2 pathway regulates the expression of different genes whose products are involved in antioxidant and inflammatory responses and the detoxification of toxic species."( The Therapeutic Potential of Carnosine as an Antidote against Drug-Induced Cardiotoxicity and Neurotoxicity: Focus on Nrf2 Pathway.
Aldini, G; Antunes, BM; Caraci, F; Caruso, G; Lazzarino, G; Lunte, SM; Privitera, A, 2022
)
0.72
" Further, the two groups had similar adverse events and reactions to the study drugs."( Efficacy and safety of polaprezinc in the treatment of gastric ulcer: A multicenter, randomized, double-blind, double-dummy, positive-controlled clinical trial.
Dong, L; Han, Z; Huang, H; Li, H; Miao, Y; Ni, R; Nie, Y; Shen, W; Zhang, Z; Zhao, X, 2022
)
0.72

Pharmacokinetics

The method was applied to determine the pharmacokinetic parameters and the time-course of N-acetylcarnosine and L-c Carnosine-related product in the eye. Peak concentration (C(max) of carnosine in treated aqueous humor occurred 60 min following topical administration.

ExcerptReferenceRelevance
" The method was applied to determine the pharmacokinetic parameters and the time-course of N-acetylcarnosine and L-carnosine-related product in the eye, following a single dosage of topical ocular administration of peptide."( Analysis of lipid peroxidation and electron microscopic survey of maturation stages during human cataractogenesis: pharmacokinetic assay of Can-C N-acetylcarnosine prodrug lubricant eye drops for cataract prevention.
Babizhayev, MA, 2005
)
0.33
" Peak concentration (C(max)) of carnosine in treated aqueous humor occurred 60 min following topical administration, with the administrated concentration (total-endogenous concentration) of 40."( Ocular pharmacokinetics of carnosine 5% eye drops following topical application in rabbit.
Junjie, Z; Ling, Z; Liya, W; Tianyang, Z, 2011
)
0.37
" The basic pharmacokinetic characteristics of carnosine were measured the in the blood and brain."( [Experimental study of the basic pharmacokinetic characteristics of dipeptide carnosine and its efficiency of penetration into brain tissues].
Abaimov, DA; Fedorova, TN; Konovalova, EV; Lopachev, AV; Pantyukhova, EY; Prokhorov, DI; Sariev, AK; Seifulla, RD; Stvolinskii, SL; Tankevich, MV, 2015
)
0.42

Compound-Compound Interactions

The effects of carnosine and its combination with essentiale on the processes of lipid peroxidation (LPO) and on the work capacity have been studied in mice. This study investigated the effects of 5-weeks sprint training combined with a vegetarian or mixed diet on muscle Carnosine.

ExcerptReferenceRelevance
"To evaluate the efficacy of polaprezinc, a mucosal protective agent, in combination with a 7-day triple therapy containing lansoprazole, amoxycillin and clarithromycin, as a treatment for Helicobacter pylori."( Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection.
Hassan, M; Ikezawa, K; Kashimura, H; Mutoh, H; Nakahara, A; Sawahata, T; Suzuki, K; Tanaka, N; Watanabe, T, 1999
)
0.3
" Although the participation of the particular transporters in observed drug-drug interactions can be difficult to confirm in humans, this review focuses mainly on pharmacokinetic interactions of clinically important drugs."( Transporter-mediated Drug Interactions.
Tsuji, A, 2002
)
0.31
"The effects of carnosine and its combination with essentiale on the processes of lipid peroxidation (LPO) and on the work capacity have been studied in mice."( [Effect of carnosine and its combination with essentiale on lipid peroxidation and work capacity of experimental animals].
Kovalev, IE; Paniushkin, VV; Rozhkova, EA; Seĭfulla, NR,
)
0.13
" This study investigated the effects of 5 weeks sprint training combined with a vegetarian or mixed diet on muscle carnosine, carnosine synthase mRNA expression and muscle buffering capacity."( Effects of sprint training combined with vegetarian or mixed diet on muscle carnosine content and buffering capacity.
Achten, E; Baguet, A; Beeckman, S; De Naeyer, H; Derave, W; Everaert, I; Petrovic, M; Reyngoudt, H; Stegen, S; Taes, Y; Vanhee, L; Volkaert, A, 2011
)
0.37
" We investigated the effect of CAR alone or in combination with α-tocopherol (CAR + TOC) on HFr-induced insulin-resistant rats."( Effect of carnosine alone or combined with α-tocopherol on hepatic steatosis and oxidative stress in fructose-induced insulin-resistant rats.
Doğru-Abbasoğlu, S; Giriş, M; Koçak-Toker, N; Kumral, A; Olgaç, V; Uysal, M, 2014
)
0.4
" We now investigated the effects of carnosine treatment alone and in combination with ACE inhibition, a clinically established nephroprotective drug in diabetic nephropathy."( Carnosine treatment in combination with ACE inhibition in diabetic rats.
Benck, U; Braunagel, M; Hammes, HP; Hauske, S; Höger, S; Köppel, H; Krämer, BK; Lanthaler, B; Peters, V; Pfister, F; Riedl, E; Schmitt, CP; Yard, BA; Zschocke, J, 2014
)
0.4
"The efficacy and safety of polaprezinc combined with triple therapy was compared with triple therapy alone in the eradication of Helicobacter pylori."( Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial.
Fang, JY; Ji, F; Li, JS; Li, YQ; Luo, HQ; Luo, HS; Lv, NH; Qian, JM; Ren, JL; Shi, RH; Tan, B; Xu, H; Zou, YY, 2017
)
0.46
" Aims To evaluate the efficacy and safety of a non-cross-linked hyaluronic acid filler in combination with L-carnosine in treating horizontal neck wrinkles."( Clinical Efficacy and Safety of Non-Cross-Linked Hyaluronic Acid Combined with L-carnosine for Horizontal Neck Wrinkles Treatment.
Gao, H; Liu, Y; Niu, H; Ren, S; Tan, Y; Wang, L; Wang, S, 2021
)
0.62

Bioavailability

Carnosine (2 g/day) was orally administered for twelve weeks in order to evaluate its bioavailability and metabolic fate. Results indicated that meat carnosine can be absorbed across the intestinal wall. The chemical derivatization is a promising strategy to improve the bioavailability of the dipeptide.

ExcerptReferenceRelevance
" Data on the effect of the constituent amino-acids of carnosine on glycylglycine absorption rate have similarly been obtained."( Impairment of jejunal absorption rate of carnosine by glycylglycine in man in vivo.
Cook, GC, 1976
)
0.26
" Since carnosine has several potential health benefits, evidence of its bioavailability suggests that it could be a bioactive food component."( Quantitation of carnosine in humans plasma after dietary consumption of beef.
Decker, EA; Park, YJ; Volpe, SL, 2005
)
0.33
" These results indicated that meat carnosine can be absorbed across the intestinal wall and that carnosine bioavailability depends on carnosine content of cooked meat."( Carnosine concentration of ingested meat affects carnosine net release into the portal vein of minipigs.
Bauchart, C; Morzel, M; Patureau Mirand, P; Rémond, D; Savary-Auzeloux, I; Thomas, E, 2007
)
0.34
" (IVP), aim at enhancing the drug bioavailability by ensuring a prolonged retention of the medication in the eye, and/or by facilitating transcorneal penetration."( Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery.
Babizhayev, MA, 2008
)
0.35
" Their role as possible antiaging strategies in healthy people in relation to neuroendocrine-immune responses and zinc ion bioavailability is reported and discussed."( Possible new antiaging strategies related to neuroendocrine-immune interactions.
Malavolta, M; Mocchegiani, E, 2008
)
0.35
" Novel approaches to ocular drug delivery increasing intraocular bioavailability of N-acetylcarnosine biologically activated metabolite carnosine become an integral development ensuring prolonged retention of the medication in the mucoadhesive precorneal area and facilitating transcorneal penetration of the natural dipeptide with the corneal promoters."( Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform.
Babizhayev, MA, 2012
)
0.38
"β-Alanyl-D-histidine (D-CAR, the enantiomer of the natural dipeptide carnosine) is a selective and potent sequestering agent of reactive carbonyl species (RCS) that is stable against carnosinase, but is poorly absorbed in the gastrointestinal tract."( Design, synthesis, ADME properties, and pharmacological activities of β-alanyl-D-histidine (D-carnosine) prodrugs with improved bioavailability.
Aldini, G; Canevotti, R; Carini, M; Gamberoni, L; Lapolla, A; Orioli, M; Pedretti, A; Previtali, M; Regazzoni, L; Rossoni, G; Vistoli, G, 2011
)
0.37
" Owing to aldose reductase pharmacophore requirements for an acidic proton, most aldose reductase inhibitors contain an acetic acid moiety, ionized at physiological pH, resulting in poor bioavailability of the drugs."( (2-Benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)-acetic acid: an aldose reductase inhibitor and antioxidant of zwitterionic nature.
Juskova, M; Milackova, I; Snirc, V; Stefek, M; Triantos, N; Tsantili-Kakoulidou, A, 2011
)
0.37
" Possible mechanisms by which carnosine may perform its anti-tumourigenic effects are outlined and its expected bioavailability and possible negative and positive side effects are considered."( Carnosine and cancer: a perspective.
Gaunitz, F; Hipkiss, AR, 2012
)
0.38
" The purpose of this study was the improvement of the topical bioavailability of the hydrophilic dipeptides L-carnosine and its related compound N-acetyl-L-carnosine."( Dermal peptide delivery using enhancer molecules and colloidal carrier systems--part I: carnosine.
Goebel, AS; Neubert, RH; Schmaus, G; Wohlrab, J, 2012
)
0.38
" The chemical derivatization of carnosine is a promising strategy to improve the bioavailability of the dipeptide and facilitating the site-specific transport to different tissues."( New derivative of carnosine for nanoparticle assemblies.
Bellia, F; Oliveri, V; Rizzarelli, E; Vecchio, G, 2013
)
0.39
" It is demonstrated in this work that both non-hydrolyzed carnosine and carcinine are characterized by greater bioavailability than pure l-carnosine subjected to enzymatic hydrolysis with carnosinase, and perform the detoxification of the α,β-unsaturated carbonyl compounds present in tobacco smoke."( The detox strategy in smoking comprising nutraceutical formulas of non-hydrolyzed carnosine or carcinine used to protect human health.
Babizhayev, MA, 2014
)
0.4
" Carnosine (2 g/day) was orally administered for twelve weeks in order to evaluate its bioavailability and metabolic fate."( A carnosine intervention study in overweight human volunteers: bioavailability and reactive carbonyl species sequestering effect.
Aldini, G; Altomare, A; Carini, M; de Courten, B; Garzon, D; Jakubova, M; Krumpolec, P; Marinello, C; Regazzoni, L; Ukropcova, B; Ukropec, J; Vallova, S, 2016
)
0.43
", (2S)-2-(3-amino propanoylamino)-3-(1H-imidazol-5-yl)propanol, a derivative of carnosine with high oral bioavailability that is resistant to carnosinases."( A carnosine analog mitigates metabolic disorders of obesity by reducing carbonyl stress.
Aldini, G; Anderson, EJ; Canevotti, R; Cannizzaro, L; Carini, M; Colzani, M; De Maddis, D; Funai, K; Gagliardi, S; Gilardoni, E; Katunga, LA; Monroe, TB; Regazzoni, L; Rossoni, G; Vistoli, G, 2018
)
0.48
" Over the years the main approaches aimed at limiting carnosine hydrolysis have been focused on obtaining CN1-stable derivatives with an increased bioavailability and unmodified or enhanced activity."( Development of a direct LC-ESI-MS method for the measurement of human serum carnosinase activity.
Aldini, G; Carini, M; Dallanoce, C; Gervasoni, S; Gilardoni, E; Maspero, M; Regazzoni, L; Vistoli, G, 2020
)
0.56
" Balenine has a much better bioavailability and stability in human circulation upon acute ingestion, compared to carnosine and anserine."( No Effect of Acute Balenine Supplementation on Maximal and Submaximal Exercise Performance in Recreational Cyclists.
Bourgois, JG; Croubels, S; De Baere, S; de Jager, S; Derave, W; Jäger, R; Lievens, E; Purpura, M; Van Damme, S, 2023
)
0.91
" The aim of this study was to elucidate the stability of balenine in the systemic circulation and its bioavailability in humans following acute supplementation."( Acute balenine supplementation in humans as a natural carnosinase-resistant alternative to carnosine.
Bourgois, JG; Croubels, S; De Baere, S; de Jager, S; Derave, W; Jäger, R; Lievens, E; Purpura, M; Van der Stede, T; Vermeulen, A, 2023
)
0.91

Dosage Studied

L-Carnosine dosing of 800 mg may be a promising agent to enhance executive functions in Schizophrenia. Administration of the combination of zinc-L-c Carnosine and vitamin E at 1X or 2X dosing did not attenuate aspirin-induced gastroduodenal mucosal injury.

ExcerptRelevanceReference
" Lumbar punctures were carried out prior to treatment and at the end of each dosage regimen and cerebrospinal fluid (CSF) evaluated for concentrations of free and total GABA, homocarnosine (GABA-histidine dipeptide), homovanillic acid (HVA), 5-hydroxyindole acetic acid (5-HIAA) and vigabatrin."( The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients.
Ben-Menachem, E; Dahlgren, L; Haegele, KD; Hardenberg, J; Huebert, N; Mumford, JP; Persson, LI; Schechter, PJ, 1989
)
0.28
"645), a potent irreversible inhibitor of gamma-aminobutyric acid transaminase, was given orally in various dosage schedules to 14 patients with Huntington disease."( Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration.
Agid, Y; Böhlen, P; Bonnet, AM; Chazot, G; Coquillat, G; Fischer, C; Koch-Weser, J; Schechter, PJ; Tell, G, 1981
)
0.26
" In the 13-week studies, dosages of 50 mg/kg/day and above resulted in emesis, mild diarrhea and salivation; reduced food consumption and associated reduction in body weight gain for high dosed females; increased blood alkaline phosphatase and decreased urinary specific gravity; histopathological changes in the kidney of the high dosed group in males and females."( Toxicity of the novel anti-peptic ulcer agent polaprezinc in beagle dogs.
Matsuda, K; Wada, H; Yamaguchi, I, 1995
)
0.29
" In this study, treatment-related changes were confined to the 200 mg/kg/day dosage and consisted of emesis, piloerection and transient body weight loss in one animal, increased plasma zinc concentrations, and zinc and copper deposition in the liver and kidneys without any associated morphological change."( Toxicity of the novel anti-peptic ulcer agent catena-(S)-[mu-[Na- (3-aminopropionyl)histidinato(2-)-N1,N2,Q:N tau]-zinc in male cynomolgus monkeys.
Crook, D; Deoraj, P; Gopinath, C; Green, OP; Matsuda, K, 1993
)
0.29
"Prospective dose-response study."( Hemodynamic effects of carcinine in the anesthetized, instrumented, open-chest rat.
Notterman, DA; Steinberg, C, 1996
)
0.29
" The dose-response curve of 51Cr release by H2O2 shifted to the right in the presence of polaprezinc."( Polaprezinc protects gastric mucosal cells from noxious agents through antioxidant properties in vitro.
Hiraishi, H; Oinuma, T; Sasai, T; Shimada, T; Sugaya, H; Terano, A, 1999
)
0.3
" Once-a-day dosing is sufficient to increase GABA."( Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures.
Collins, T; Hyder, F; Mattson, RH; Petroff, OA; Rothman, DL, 1999
)
0.3
" We reported that daily dosing increased brain gamma-aminobutyric acid (GABA) in patients with epilepsy."( Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients.
Hyder, F; Mattson, RH; Petroff, OA; Rothman, DL, 2000
)
0.31
" The method was applied to determine the pharmacokinetic parameters and the time-course of N-acetylcarnosine and L-carnosine-related product in the eye, following a single dosage of topical ocular administration of peptide."( Analysis of lipid peroxidation and electron microscopic survey of maturation stages during human cataractogenesis: pharmacokinetic assay of Can-C N-acetylcarnosine prodrug lubricant eye drops for cataract prevention.
Babizhayev, MA, 2005
)
0.33
" Potentiating Zn(2+) concentrations shifted the dose-response curves for the three agonists to the left and decreased the Hill coefficient for glycine and beta-alanine but not taurine."( Modulation of inhibitory glycine receptors in cultured embryonic mouse hippocampal neurons by zinc, thiol containing redox agents and carnosine.
Thio, LL; Zhang, HX, 2006
)
0.33
" No significant differences were observed in the dosage of medicines or other clinical data during the treatment."( Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin.
Kakibuchi, N; Kawakami, T; Kawashima, A; Kita, K; Koyabu, T; Murakami, Y; Okita, M; Takaguchi, K, 2007
)
0.34
" Dosing for NT-020 and vehicle consisted of daily oral administration (using a gavage) over a 2-week period."( Dietary supplementation exerts neuroprotective effects in ischemic stroke model.
Bickford, PC; Borlongan, CV; Hara, K; Maki, M; Masuda, T; Sanberg, CD; Sanberg, PR; Yasuhara, T, 2008
)
0.35
" After exogenous dosing of [(3)H]carnosine (1 nmol/g iv bolus), a marked increase was observed in its systemic clearance in Pept2 null mice (0."( Influence of genetic knockout of Pept2 on the in vivo disposition of endogenous and exogenous carnosine in wild-type and Pept2 null mice.
Hu, Y; Jiang, H; Kamal, MA; Keep, RF; Smith, DE, 2009
)
0.35
"Functional synergy between excipients in gellan gum formulations buffered with l-carnosine has potential for topical ocular dosage forms with sustained precorneal residence."( L-Carnosine: multifunctional dipeptide buffer for sustained-duration topical ophthalmic formulations.
Carreiro, ST; Chu, J; Collette Iii, WW; Gukasyan, HJ; Niesman, MR; Prasanna, G; Sartnurak, S; Singh, SR; Younis, HS, 2009
)
0.35
" During treatment, the dosage of erythropoietin was reduced significantly from baseline at all assessment points."( Zinc deficiency anemia and effects of zinc therapy in maintenance hemodialysis patients.
Fujiki, S; Fukushima, T; Horike, H; Kashihara, N; Kitada, S; Sasaki, T, 2009
)
0.35
" They can be prevented by using controlled release capsules and smaller dosing strategies."( Role of beta-alanine supplementation on muscle carnosine and exercise performance.
Artioli, GG; Gualano, B; Lancha, AH; Smith, A; Stout, J, 2010
)
0.36
"Administration of the combination of zinc-L-carnosine and vitamin E at 1X or 2X dosing did not attenuate aspirin-induced gastroduodenal mucosal injury."( Effects of zinc-L-carnosine and vitamin E on aspirin-induced gastroduodenal injury in dogs.
Baan, M; Johnson, SE; Sherding, RG,
)
0.13
" This placebo-controlled, double-blind study compared two different 8-week BA dosing regimens on the time course of muscle carnosine loading and 8-week washout, leading to a BA dose-response study with serial muscle carnosine assessments throughout."( Effect of two β-alanine dosing protocols on muscle carnosine synthesis and washout.
Anwander, H; Boesch, C; Buehler, T; Decombaz, J; Egger, A; Kreis, R; Stellingwerff, T, 2012
)
0.38
" Supporting this, a recent dose-response study demonstrated a large linear dependency (R2=0."( Optimizing human in vivo dosing and delivery of β-alanine supplements for muscle carnosine synthesis.
Boesch, C; Decombaz, J; Harris, RC; Stellingwerff, T, 2012
)
0.38
" Though carnosine at lower dosage (0."( Platelet monoamine oxidase-A activity and aging: effect of carnosine.
Banerjee, S; Poddar, MK, 2013
)
0.39
"5μg/kg/day) and restored toward the activity that observed in young, though its lower dosage (0."( Carnosine: effect on aging-induced increase in brain regional monoamine oxidase-A activity.
Banerjee, S; Poddar, MK, 2015
)
0.42
" Moreover, it also has attempted to establish a specific dosage that maximizing the potential benefits, minimize paresthesia, the main side effect presented in response to supplementation."( [Effects of ß-alanine supplementation on athletic performance].
Domínguez, R; Garnacho-Castaño, MV; Hernández Lougedo, J; Maté-Muñoz, JL, 2014
)
0.4
" Further, in the polaprezinc group, ESA dosage and ERI were significantly decreased at 10 months and nine months, respectively, as compared with the baseline value."( Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
Abe, M; Higuchi, T; Kikuchi, F; Kobayashi, H; Maruyama, N; Okada, K; Soma, M; Tei, R, 2015
)
0.42
"The research utilizing the N-acetylcarnosine lubricant eye drops powerful therapeutic platform provides the findings related to the intraocular uptake exposure sources as well as a timing dosage and duration systemic absorption of said preparation from the conjunctional sac reaching the hypothalamus with activities transfer into the hypothalamic-neuroendocrine pathways affecting across the hypothalamus metabolic pathway the telomere biology and cataract disease occurrence, reversal and prevention and the average expected lifespan of an individual."( Telomere Attrition in Human Lens Epithelial Cells Associated with Oxidative Stress Provide a New Therapeutic Target for the Treatment, Dissolving and Prevention of Cataract with N-Acetylcarnosine Lubricant Eye Drops. Kinetic, Pharmacological and Activity-
Babizhayev, MA; Yegorov, YE, 2016
)
0.43
" A clear dose-response effect was observed, and efficacy was reduced when carnosine was administered more than 6 h after ischemia."( Systematic review and stratified meta-analysis of the efficacy of carnosine in animal models of ischemic stroke.
Bahor, Z; Davis, CK; Laud, PJ; Majid, A; Rajanikant, GK, 2016
)
0.43
"Personalised dosing of performance-enhancing food supplements is a hot topic."( Fragmented Dosing of β-alanine Induces A Body Weight-Independent Pharmacokinetic Response.
Derave, W; Pringels, L; Stautemas, J; Van de Loock, A; Van der Stede, T, 2019
)
0.51
"Fifty-eight patients with MDD (DSM-V) and Hamilton Depression Rating Scale (HAM-D) score ≥ 19 were randomized to receive either 400 mg twice daily L-Carnosine or placebo in addition to citalopram (maximum dosage of 40 mg/day) for six weeks in a randomized double-blind, and placebo-controlled study."( L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial.
Akhondzadeh, S; Aqamolaei, A; Araminia, B; Ardebili, ME; Ghaffari, S; Mortazavi, SH; Mortezaei, A; Naderi, S; Sahebolzamani, E; Shalbafan, M; Shariati, B; Shirazi, E, 2020
)
0.56
" Carnosine showed a trend for dose-response between non-consumers, low consumers and high consumers for all meat categories, while in combination with other biomarkers the difference was significant."( The anserine to carnosine ratio: an excellent discriminator between white and red meats consumed by free-living overweight participants of the PREVIEW study.
Cuparencu, C; Dragsted, LO; Poppitt, SD; Raben, A; Rinnan, Å; Silvestre, MP, 2021
)
0.62
" The linear dose-response relationship and the subgroup effects were also assessed."( Efficacy and Safety of Polaprezinc (Zinc Compound) on Zinc Deficiency: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials Using Individual Patient Data.
Furihata, K; Miwa, T; Naito, Y; Oba, K; Sakagami, M; Tsuchikawa, M, 2020
)
0.56
" Three studies were conducted to establish dosing and timing guidelines concerning carnosine and anserine intake and to unravel the mechanism underlying the ergogenic effects."( The ergogenic effect of acute carnosine and anserine supplementation: dosing, timing, and underlying mechanism.
Aldini, G; Blancquaert, L; Bourgois, JG; Croubels, S; De Baere, S; de Jager, S; Derave, W; Gilardoni, E; Lievens, E; Regazzoni, LG; Van der Stede, T, 2022
)
0.72
" L-Carnosine dosing of 800 mg may be a promising agent to enhance executive functions in Schizophrenia."( Cognitive and negative symptoms in schizophrenia with L-Carnosine adjuvant therapy - A randomized double-blind placebo-controlled study.
Chandan, AK; Durairaj, J; Maran, S; Pari, M; Rao, S; Tharoor, H, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (8)

RoleDescription
anticonvulsantA drug used to prevent seizures or reduce their severity.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Daphnia magna metaboliteA Daphnia metabolite produced by the species Daphnia magna.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
amino acid zwitterionThe zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (9)

PathwayProteinsCompounds
Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism4485
Histidine Metabolism1735
beta-Alanine Metabolism927
GABA-Transaminase Deficiency927
Histidinemia1735
Ureidopropionase Deficiency927
Carnosinuria, Carnosinemia927
Histidine degradation ( Histidine degradation )2326
Carnosine metabolism of glial cells09

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency31.62280.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency31.62280.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency39.81070.00636.904339.8107AID883
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency2.23870.00798.23321,122.0200AID2551
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency39.81070.00638.235039.8107AID883
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 2Homo sapiens (human)IC50 (µMol)28.000028.000063.3333123.0000AID1794819
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki66.00003.00006.47788.5000AID681124
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)KA1.30000.02001.72197.4000AID50347; AID50348
Carbonic anhydrase 2Homo sapiens (human)KA35.00000.01101.42737.8000AID47753; AID47897
Carbonic anhydrase 4Homo sapiens (human)KA15.00000.07904.45607.3000AID257047
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (35)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
bicarbonate transportCarbonic anhydrase 4Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of locomotion5-hydroxytryptamine receptor 1DHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1DHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 2Homo sapiens (human)
protein transportSolute carrier family 15 member 2Homo sapiens (human)
peptide transportSolute carrier family 15 member 2Homo sapiens (human)
peptidoglycan transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 15 member 2Homo sapiens (human)
dipeptide transportSolute carrier family 15 member 2Homo sapiens (human)
renal absorptionSolute carrier family 15 member 2Homo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwaySolute carrier family 15 member 2Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
antibacterial innate immune responseSolute carrier family 15 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 15 member 2Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 4Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 4Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
protein bindingSolute carrier family 15 member 2Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 2Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 4Homo sapiens (human)
rough endoplasmic reticulumCarbonic anhydrase 4Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartmentCarbonic anhydrase 4Homo sapiens (human)
Golgi apparatusCarbonic anhydrase 4Homo sapiens (human)
trans-Golgi networkCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
external side of plasma membraneCarbonic anhydrase 4Homo sapiens (human)
cell surfaceCarbonic anhydrase 4Homo sapiens (human)
membraneCarbonic anhydrase 4Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 4Homo sapiens (human)
transport vesicle membraneCarbonic anhydrase 4Homo sapiens (human)
secretory granule membraneCarbonic anhydrase 4Homo sapiens (human)
brush border membraneCarbonic anhydrase 4Homo sapiens (human)
perinuclear region of cytoplasmCarbonic anhydrase 4Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 4Homo sapiens (human)
plasma membraneCarbonic anhydrase 4Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1DHomo sapiens (human)
phagocytic vesicle membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
membraneSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
side of membraneCarbonic anhydrase 4Bos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (98)

Assay IDTitleYearJournalArticle
AID294880Protective effect on copper-induced LDL oxidation at 20:1 copper to drug ratio relative to 40 uM copper2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates.
AID679880TP_TRANSPORTER: inhibition of Ceftibuten uptake (Ceftibuten: 1000 uM, Carnosine: 10000 uM) in Xenopus laevis oocytes1995The Journal of pharmacology and experimental therapeutics, Dec, Volume: 275, Issue:3
Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney.
AID1534322Quenching activity of compound in pH 7.4 PBS assessed as 4-HNE consumption at 2 mmol/L after 30 mins by HPLC analysis relative to control2019European journal of medicinal chemistry, Feb-01, Volume: 163Neuroprotective effects of a novel carnosine-hydrazide derivative on hippocampal CA1 damage after transient cerebral ischemia.
AID1327549Reactive carbonyl species trapping activity of compound assessed as MGO adduct formation at 10 mM preincubated for 24 hrs with MGO measured after 0.5 hrs by LCMS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID450166Cytotoxicity in human EAhy926 cells assessed as viable cells at 1 mM after overnight incubation by MTT assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation.
AID761643Selectivity ratio of antioxidant activity assessed as HNE quenching to antioxidant activity assessed as PYR quenching2013European journal of medicinal chemistry, Aug, Volume: 66Exploring the space of histidine containing dipeptides in search of novel efficient RCS sequestering agents.
AID1327557Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 0.05 mM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID294865Effect on copper-induced human LDL peroxidation assessed as inhibition of malonaldehyde production at 200 uM after 4 hrs2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates.
AID257047Activation constant against recombinant human CA IV isozyme by the esterase method2005Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23
Carbonic anhydrase activators: X-ray crystal structure of the adduct of human isozyme II with L-histidine as a platform for the design of stronger activators.
AID294883Protective effect on copper-induced LDL oxidation at 2:1 copper to drug ratio relative to 40 uM copper2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates.
AID680832TP_TRANSPORTER: inhibition of VACV uptake (VACV: 0.2 uM, Carnosine: 10000 uM) in Xenopus laevis oocytes1998Biochemical and biophysical research communications, Sep-18, Volume: 250, Issue:2
Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir.
AID1485212Drug metabolism assessed as human recombinant carnosinase mediated compound hydrolysis at 0.5 mM after 1.5 hrs by RP-HPLC analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID1485217Antiglycating activity in phosphate buffer assessed as ACR levels at 10 mM at pH 7.4 after 24 hr by RP-HPLC analysis relative to control2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID1327552Reactive carbonyl species trapping activity of compound assessed as MDA adduct formation at 10 mM preincubated for 24 hrs with MDA measured after 0.25 hrs by LCMS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID566328Antioxidant activity against CuSO4-induced LDL oxidation measured per mg og LDL product assessed as propagation rate of the oxidation at 100 uM by antioxidation assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Synthesis, physicochemical characterization, and biological activities of new carnosine derivatives stable in human serum as potential neuroprotective agents.
AID1327550Reactive carbonyl species trapping activity of compound assessed as MGO adduct formation at 10 mM preincubated for 24 hrs with MGO measured after 1 hr by LCMS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID294861Effect on copper-induced human LDL peroxidation assessed as inhibition of malonaldehyde production at 10 uM after 4 hrs2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates.
AID1327558Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 0.08 mM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID566333Cytoprotective effect in mouse primary hippocampal neuron assessed as reduction in 4-hydroxy-trans-2,3-nonenal-induced damage at 100 uM after 24 hrs2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Synthesis, physicochemical characterization, and biological activities of new carnosine derivatives stable in human serum as potential neuroprotective agents.
AID566325Lipophilicity, log D of the compound by shake-flask technique2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Synthesis, physicochemical characterization, and biological activities of new carnosine derivatives stable in human serum as potential neuroprotective agents.
AID1327551Reactive carbonyl species trapping activity of compound assessed as MGO adduct formation at 10 mM preincubated for 24 hrs with MGO measured after 5 hrs by LCMS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID1485210Inhibition of cupric ion-mediated amyloid beta (1 to 40) aggregation at 20 mM at pH 6.6 after 3 hrs by light scattering assay2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID1327079Neuroprotective activity in human SH-SY5Y cells assessed as reduction in oxygen glucose deprivation-induced cell death incubated for 16 hrs under hypoxic condition followed by incubation for 24 hrs under normoxic condition by MTT assay2016Journal of natural products, 08-26, Volume: 79, Issue:8
Chemical Constituents Isolated from the Root Bark of Cudrania tricuspidata and Their Potential Neuroprotective Effects.
AID671306Reduction of ischemia-reperfusion-induced TNFalpha level increase in Wistar rat serum at 1 g/kg, iv by ELISA2012European journal of medicinal chemistry, Aug, Volume: 54Carnosine analogues containing NO-donor substructures: synthesis, physico-chemical characterization and preliminary pharmacological profile.
AID566327Antioxidant activity against CuSO4-induced LDL oxidation assessed as delta-lag time at 100 uM by antioxidation assay2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Synthesis, physicochemical characterization, and biological activities of new carnosine derivatives stable in human serum as potential neuroprotective agents.
AID450158Inhibition of alpha-dicarbonyls-induced advanced glycation end product formation assessed as protection against 50 eq. MG-induced insulin degradation at 3.75 mM after 24 hrs by RP-HPLC2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation.
AID1485190Antiglycating activity in phosphate buffer assessed as decrease in ACR levels at 10 mM at pH 7.4 up to 4 hrs by RP-HPLC analysis relative to control2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID294884Protective effect on copper-induced LDL oxidation at 1:1.25 copper to drug ratio relative to 40 uM copper2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates.
AID294885Protective effect on copper-induced LDL oxidation at 1:2.5 copper to drug ratio relative to 40 uM copper2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates.
AID1327548Reactive carbonyl species trapping activity of compound assessed as MGO adduct formation at 10 mM preincubated for 24 hrs with MGO measured after 0.25 hrs by LCMS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID671295Half life in human serum at 0.5 mM by RP-HPLC analysis2012European journal of medicinal chemistry, Aug, Volume: 54Carnosine analogues containing NO-donor substructures: synthesis, physico-chemical characterization and preliminary pharmacological profile.
AID450165Cytoprotective activity against MG-induced cytotoxicity in human EAhy926 cells assessed as viable cells at 1 mM after overnight incubation by MTT assay2009Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6
N-Terminal 2,3-diaminopropionic acid (Dap) peptides as efficient methylglyoxal scavengers to inhibit advanced glycation endproduct (AGE) formation.
AID1485216Inhibition of amyloid beta (1 to 42) (unknown origin) self induced aggregation assessed as Tlag at 40 to 5000 uM in presence of trehalose by ThT-based fluorometric method (Rvb = 8.3 +/- 0.7 hrs)2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID294859Effect on copper-induced human LDL peroxidation assessed as inhibition of malonaldehyde production at 2 uM after 4 hrs2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates.
AID633135Antioxidant activity in Wistar rat erythrocytes assessed as prolongation of initial inhibition period-lag phase of t-BuOOH-induced hemolysis at 10 mM preincubated for 30 mins before induction measured up to 5 hrs by spectrophotometry2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
(2-Benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)-acetic acid: an aldose reductase inhibitor and antioxidant of zwitterionic nature.
AID50348In vitro carbonic anhydrase activation in human cloned Carbonic anhydrase I (hCA I)2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Carbonic anhydrase activators: high affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scaffold.
AID1485200Inhibition of amyloid beta (1 to 42) (unknown origin) self induced aggregation assessed as reduction in protofibrils formation at 500 uM after 30 hrs by atomic force microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID681152TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Drug metabolism and pharmacokinetics, , Volume: 17, Issue:4
Transporter-mediated Drug Interactions.
AID671302Vasodilator activity in Wistar rat endothelium-denuded thoracic aorta assessed as inhibition of L-phenylephrine-induced contraction2012European journal of medicinal chemistry, Aug, Volume: 54Carnosine analogues containing NO-donor substructures: synthesis, physico-chemical characterization and preliminary pharmacological profile.
AID1485195Inhibition of amyloid beta (1 to 42) (unknown origin) self induced aggregation assessed as fluorescence emission rate constant K at 40 to 5000 uM after 3 hrs by ThT-based fluorometric method (Rvb = 1.3 +/- 0.1 No_unit)2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID566330Antioxidant activity assessed as 4-hydroxy-trans-2,3-nonenal scavenging activity at 1 mM after 6 hrs by HPLC relative to control2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Synthesis, physicochemical characterization, and biological activities of new carnosine derivatives stable in human serum as potential neuroprotective agents.
AID681124TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT2-expressing LLC-PK1 cells2000Pflugers Archiv : European journal of physiology, Sep, Volume: 440, Issue:5
Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2.
AID294881Protective effect on copper-induced LDL oxidation at 8:1 copper to drug ratio relative to 40 uM copper2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates.
AID1327560Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 0.5 mM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID294882Protective effect on copper-induced LDL oxidation at 4:1 copper to drug ratio relative to 40 uM copper2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates.
AID1485213Inhibition of amyloid beta (1 to 42) (unknown origin) self induced aggregation assessed as difference between final and initial fluorescence emission at 40 to 5000 uM after 3 hrs in presence of trehalose by ThT-based fluorometric method (Rvb = 52 +/- 7 a.2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID1485215Inhibition of amyloid beta (1 to 42) (unknown origin) self induced aggregation assessed as time at which amplitude of ThT emission is 50% of difference between final and initial fluorescence emission at 40 to 5000 uM in presence of trehalose by ThT-based 2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID48116Tested in vitro for activation of carbonic anhydrase IV (bCA IV), purified from bovine lung microsomes2002Bioorganic & medicinal chemistry letters, Apr-22, Volume: 12, Issue:8
Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1.
AID294862Effect on copper-induced human LDL peroxidation assessed as inhibition of malonaldehyde production at 20 uM after 4 hrs2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates.
AID1327556Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 0.02 mM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID566332Toxicity in mouse primary hippocampal neuron assessed as adverse effect at 100 uM after 24 hrs2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Synthesis, physicochemical characterization, and biological activities of new carnosine derivatives stable in human serum as potential neuroprotective agents.
AID294864Effect on copper-induced human LDL peroxidation assessed as inhibition of malonaldehyde production at 100 uM after 4 hrs2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates.
AID1485193Antiglycating activity in phosphate buffer assessed as ACR-compound adduct formation at 10 mM at pH 7.4 after 1 to 24 hrs by HPLC-MS/MS spectra analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID566329Antioxidant activity assessed as 4-hydroxy-trans-2,3-nonenal scavenging activity at 1 mM after 1 hr by HPLC relative to control2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Synthesis, physicochemical characterization, and biological activities of new carnosine derivatives stable in human serum as potential neuroprotective agents.
AID1327545Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 200 uM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID1485189Antiglycating activity in phosphate buffer assessed as decrease in ACR levels at 10 mM at pH 7.4 after 1 hr by RP-HPLC analysis relative to control2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1485197Inhibition of amyloid beta (1 to 42) (unknown origin) self induced aggregation assessed as time at which amplitude of ThT emission is 50% of difference between final and initial fluorescence emission at 40 to 5000 uM after 3 hrs by ThT-based fluorometric 2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID1534321Quenching activity of compound in pH 7.4 PBS assessed as 4-HNE consumption at 2 mmol/L after 1 hr by HPLC analysis2019European journal of medicinal chemistry, Feb-01, Volume: 163Neuroprotective effects of a novel carnosine-hydrazide derivative on hippocampal CA1 damage after transient cerebral ischemia.
AID761646Antioxidant activity assessed as PYR quenching after 180 mins by HPLC analysis2013European journal of medicinal chemistry, Aug, Volume: 66Exploring the space of histidine containing dipeptides in search of novel efficient RCS sequestering agents.
AID1485202Inhibition of amyloid beta (1 to 42) (unknown origin) self induced aggregation after 3 hrs by ThT-based fluorometric method2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID50347Tested in vitro for activation of Human cloned isozyme carbonic anhydrase I (hCA I)2002Bioorganic & medicinal chemistry letters, Apr-22, Volume: 12, Issue:8
Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1.
AID1485214Inhibition of amyloid beta (1 to 42) (unknown origin) self induced aggregation assessed as fluorescence emission rate constant K at 40 to 5000 uM after 3 hrs in presence of trehalose by ThT-based fluorometric method (Rvb = 1.3 +/- 0.1 No_unit)2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID1507781Inhibition of IL-15 (unknown origin)/IL-15Ralpha interaction in human PBMC cells assessed as reduction of TNF-alpha synthesis preincubated for 30 mins followed by IL-15 addition measured after 48 hrs by ELISA2017European journal of medicinal chemistry, Aug-18, Volume: 136Pharmacophore guided discovery of small-molecule interleukin 15 inhibitors.
AID678975TP_TRANSPORTER: uptake (electrogenesis) in Xenopus laevis oocytes2000Biochemical and biophysical research communications, Sep-24, Volume: 276, Issue:2
Cloning and characterization of the gene encoding the mouse peptide transporter PEPT2.
AID681125TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT1-expressing LLC-PK1 cells2000Pflugers Archiv : European journal of physiology, Sep, Volume: 440, Issue:5
Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2.
AID1327553Reactive carbonyl species trapping activity of compound assessed as MDA adduct formation at 10 mM preincubated for 24 hrs with MDA measured after 0.5 hrs by LCMS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID1327562Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 2 mM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID294860Effect on copper-induced human LDL peroxidation assessed as inhibition of malonaldehyde production at 5 uM after 4 hrs2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates.
AID1327541Reactive carbonyl species trapping activity of compound assessed as MGO adduct formation at 10 mM preincubated for 24 hrs with MGO measured after 24 hrs by LCMS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID1485199Inhibition of amyloid beta (1 to 42) (unknown origin) self induced aggregation assessed as reduction in flat ribbons formation at 500 uM after 30 hrs by atomic force microscopic analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID300530Malondialdehyde scavenging activity in iron/ascorbate-induced oxidation in PC liposomes at 10 mM by TBARS test2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Malondialdehyde scavenging and aldose-derived Schiff bases' transglycation properties of synthetic histidyl-hydrazide carnosine analogs.
AID1327559Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 0.1 mM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID1327554Reactive carbonyl species trapping activity of compound assessed as MDA adduct formation at 10 mM preincubated for 24 hrs with MDA measured after 5 hrs by LCMS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID671304Protection against hypoxia-induced brain damage in Wistar rat ischemia-reperfusion injury model assessed as reduction of cerebral infarct volume at 1 g/kg, iv administered at beginning of reperfusion and again after 6 hrs measured 24 hrs after reperfusion2012European journal of medicinal chemistry, Aug, Volume: 54Carnosine analogues containing NO-donor substructures: synthesis, physico-chemical characterization and preliminary pharmacological profile.
AID294863Effect on copper-induced human LDL peroxidation assessed as inhibition of malonaldehyde production at 50 uM after 4 hrs2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates.
AID48117In vitro carbonic anhydrase IV activation in bovine lung microsomes.2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Carbonic anhydrase activators: high affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scaffold.
AID1327555Reactive carbonyl species trapping activity of compound assessed as MDA adduct formation at 10 mM preincubated for 24 hrs with MDA measured after 24 hrs by LCMS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID47897In vitro carbonic anhydrase activation in human cloned Carbonic anhydrase II (hCA II)2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Carbonic anhydrase activators: high affinity isozymes I, II, and IV activators, incorporating a beta-alanyl-histidine scaffold.
AID1327543Reactive carbonyl species trapping activity of compound assessed as MDA adduct formation at 10 mM preincubated for 24 hrs with MDA measured after 1 hr by LCMS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID1485198Inhibition of amyloid beta (1 to 42) (unknown origin) self induced aggregation assessed as lag time at 40 to 5000 uM after 3 hrs by ThT-based fluorometric method (Rvb = 8.3 +/- 0.7 hrs)2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID679867TP_TRANSPORTER: inhibition of Cephradine uptake (Cephradine: 3000 uM, Carnosine: 10000 uM) in Xenopus laevis oocytes1995The Journal of pharmacology and experimental therapeutics, Dec, Volume: 275, Issue:3
Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney.
AID1485196Inhibition of amyloid beta (1 to 42) (unknown origin) self induced aggregation assessed as difference between final and initial fluorescence emission at 40 to 5000 uM after 3 hrs by ThT-based fluorometric method (Rvb = 52 +/- 7 a.u.)2017European journal of medicinal chemistry, Jul-28, Volume: 135Multitarget trehalose-carnosine conjugates inhibit Aβ aggregation, tune copper(II) activity and decrease acrolein toxicity.
AID1327542Reactive carbonyl species trapping activity of compound assessed as MGO adduct formation at 10 mM preincubated for 24 hrs with MGO measured after 15 mins by LCMS analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID1327544Antioxidant activity assessed as inhibition of AAPH-induced peroxyl radical generation measured as trolox equivalent at 10 uM preincubated for 30 mins followed by AAPH addition measured evey 60 secs for 60 cycles by ORAC-FL assay2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID1507780Cytotoxicity against human PBMC cells up to 200 uM after 48 hrs by CellTiter 96 AQueous one solution cell proliferation assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Pharmacophore guided discovery of small-molecule interleukin 15 inhibitors.
AID1327561Metal chelating activity of compound assessed as compound-Cu2+ complex formation at 1 mM after 10 mins in presence of CuSO4.5H2O by complexometric indicator murexide based UV-Vis spectrophotometric analysis2016European journal of medicinal chemistry, Oct-21, Volume: 122Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease.
AID680670TP_TRANSPORTER: inhibition of fMLP uptake (fMLP: 0.1 uM, Carnosine: 10000 uM) in Caco-2 cells1998The Journal of clinical investigation, Dec-01, Volume: 102, Issue:11
hPepT1-mediated epithelial transport of bacteria-derived chemotactic peptides enhances neutrophil-epithelial interactions.
AID761645Antioxidant activity assessed as HNE quenching at 1 mM after 180 mins by HPLC analysis2013European journal of medicinal chemistry, Aug, Volume: 66Exploring the space of histidine containing dipeptides in search of novel efficient RCS sequestering agents.
AID681683TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, Carnosine: 500 uM) in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID47753Tested in vitro for activation of Human cloned isozyme carbonic anhydrase II (hCA II)2002Bioorganic & medicinal chemistry letters, Apr-22, Volume: 12, Issue:8
Carbonic anhydrase activators: human isozyme II is strongly activated by oligopeptides incorporating the carboxyterminal sequence of the bicarbonate anion exchanger AE1.
AID566326Stability of the compound in human serum after 3 hrs2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Synthesis, physicochemical characterization, and biological activities of new carnosine derivatives stable in human serum as potential neuroprotective agents.
AID1507782Inhibition of IL-15 (unknown origin)/IL-15Ralpha interaction in human PBMC cells assessed as reduction of IL-17 synthesis preincubated for 30 mins followed by IL-15 addition measured after 48 hrs by ELISA2017European journal of medicinal chemistry, Aug-18, Volume: 136Pharmacophore guided discovery of small-molecule interleukin 15 inhibitors.
AID566331Antioxidant activity assessed as 4-hydroxy-trans-2,3-nonenal scavenging activity at 1 mM after 24 hrs by HPLC relative to control2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Synthesis, physicochemical characterization, and biological activities of new carnosine derivatives stable in human serum as potential neuroprotective agents.
AID294886Protective effect on copper-induced LDL oxidation at 1:5 copper to drug ratio relative to 40 uM copper2007European journal of medicinal chemistry, Jul, Volume: 42, Issue:7
Synthesis and antioxidant activity of new homocarnosine beta-cyclodextrin conjugates.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,914)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990326 (17.03)18.7374
1990's315 (16.46)18.2507
2000's391 (20.43)29.6817
2010's614 (32.08)24.3611
2020's268 (14.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials136 (6.62%)5.53%
Reviews204 (9.93%)6.00%
Case Studies25 (1.22%)4.05%
Observational3 (0.15%)0.25%
Other1,686 (82.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]